December 2, 2024 10:48 AM ESTUpdated 11:00 AM
R&D

Novo­cure says elec­tric field ther­a­py ex­tends life for pan­cre­at­ic can­cer pa­tients by two months

Lei Lei Wu

News Reporter

Novo­cure an­nounced Mon­day morn­ing that its elec­tri­cal fields wear­able de­vice com­bined with chemother­a­py passed a late-stage tri­al in pan­cre­at­ic can­cer, and the biotech now plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Ole­ma, No­var­tis ink an­oth­er agree­ment, this time for a late-stage breast can­cer tri­al

A service from the Financial Times